Brief: Qualigen Therapeutics Secures Worldwide Rights To G4-Selective Transcription Inhibitors From University College London To Develop As Cancer Therapeutics
18/01/2022 14:39
Jan 18 (Reuters) - Qualigen Therapeutics Inc QLGN.O :
* QUALIGEN THERAPEUTICS SECURES WORLDWIDE RIGHTS TO
G4-SELECTIVE
TRANSCRIPTION INHIBITORS FROM UNIVERSITY COLLEGE LONDON TO
DEVELOP AS CANCER THERAPEUTICS
Source text for Eikon: ID:nGNX1CFSXh
Further company coverage: QLGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aixcrypto Holdings
See all newsBrief: Aixcrypto - Enters Common Shares Purchase Agreement With Gold King Arthur Holding - SEC Filing
Chief Executive Officer And Director
Brief: Aixcrypto Holdings - Enters Note Purchase Agreement With CABG Acquisition Corp On May 12, 2026 - SEC Filing
Brief: Aixcrypto Holdings Reports First Quarter 2026 Results
AIxCrypto Q1 net loss widens as expenses rise